Skip to content

A single-arm, prospective clinical study of carrelizumab combined with apatinib and SOX in the treatment of advanced unresectable gastric cancer

A single-arm, prospective clinical study of carrelizumab combined with apatinib and SOX in the treatment of advanced unresectable gastric cancer

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100048020
Enrollment
Unknown
Registered
2021-06-28
Start date
2021-07-01
Completion date
Unknown
Last updated
2022-08-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stomach cancer

Interventions

Sponsors

The Affiliated Hospital of Youjiang Medical College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. aged 18 to 75 years old; 2. ECOG score 0-1 points; 3. Pathological and/or cytologically confirmed diagnosis of gastric cancer; 4. The expected survival period >=3 months; 5. The main organs function normally, that is, they meet the following standards: (1) The standard of routine blood examination should meet: (no blood transfusion within 14 days) WBC =4.0×10^9/L; ANC =1.5×10^9/L; PLT =100×10^9/L; Hb =90g/L; (2) The biochemical inspection shall meet the following standards: BIL 50ml/min (Cockcroft-Gault formula); 6. Before joining the group, the heart function was good, no myocardial infarction occurred within half a year, and hypertension and other coronary heart diseases are currently within the controllable range; 7. No other uncontrollable benign diseases, such as lung, kidney, liver infection, etc., were not accompanied before enrollment; 8. Willing to sign an informed consent form, good medical compliance.

Exclusion criteria

Exclusion criteria: 1. Suffered from other malignant tumors in the past or at the same time, except for cured skin basal cell carcinoma and cervical carcinoma in situ; 2. Those who have been confirmed to be allergic to carrelizumab, apatinib, ticgio, oxaliplatin and/or its excipients; 3. Researchers believe that patients with a clear gastrointestinal bleeding tendency or/and abnormal coagulation function (INR>1.5) have a bleeding tendency; 4. Those who have undergone other anti-cancer treatments two months before enrollment or cannot be guaranteed to follow the research requirements after enrollment; 5. Pregnant or lactating women; 6. The investigator thinks it is not suitable.

Design outcomes

Primary

MeasureTime frame
Progression-free survival (PFS);Over all survival (OS);Adverse event;

Secondary

MeasureTime frame
Objective Response Rate (ORR);Surgical conversion rate;

Countries

China

Contacts

Public ContactHuang Shiqing

The Affiliated Hospital of Youjiang Medical College

517441638@qq.com+86 19918474422

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026